Menu
Back to User profile » Dr Michael Grabner
Papers published by Dr Michael Grabner:
Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study
Stephenson JJ, Gable JC, Zincavage R, Price GL, Churchill C, Zhu E, Stenger K, Singhal M, Nepal B, Grabner M, Fisch MJ, Debono D, Geschwender AR, Cuyun Carter G
Patient Preference and Adherence 2021, 15:2417-2429
Published Date: 3 November 2021
Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction
Grabner M, Burchard J, Nguyen C, Chung H, Gangan N, Boniface JJ, Zupancic JAF, Stanek E
ClinicoEconomics and Outcomes Research 2021, 13:809-820
Published Date: 14 September 2021
Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States
Hess LM, Grabner M, Wang L, Liepa AM, Li XI, Cui ZL, Bowman L, Schelman WR
Pragmatic and Observational Research 2020, 11:27-43
Published Date: 30 April 2020
Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
Kalirai S, Ivanova JI, Perez-Nieves M, Stephenson JJ, Hadjiyianni I, Grabner M, Pollom RD, Geremakis C, Reed BL, Fisher L
Diabetes, Metabolic Syndrome and Obesity 2020, 13:1023-1033
Published Date: 3 April 2020
Occurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal Cancer
Fisch MJ, Grabner M, Mytelka DS, Raval AD, Bowman L, Kern DM, Churchill C, Singer J, Wetmore S, Barron J, Eleff M
Cancer Management and Research 2020, 12:1535-1541
Published Date: 3 March 2020
Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease
Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP
Vascular Health and Risk Management 2018, 14:23-36
Published Date: 5 February 2018
The SWEET SPOTS study: a real-world interpretation of the 2012 American Diabetes Association Position Statement regarding individualized A1C targets
Bieszk N, Grabner M, Wei W, Bonine NG, Stephenson JJ
Risk Management and Healthcare Policy 2016, 9:243-251
Published Date: 8 November 2016
Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
Guo A, Grabner M, Palli SR, Elder J, Sidovar M, Aupperle P, Krieger S
ClinicoEconomics and Outcomes Research 2016, 8:177-186
Published Date: 12 May 2016
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
Palli SR, Grabner M, Quimbo RA, Rugo HS
Cancer Management and Research 2015, 7:175-188
Published Date: 16 June 2015
Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device
Grabner M, Chen Y, Nguyen M, Abbott SD, Quimbo R
ClinicoEconomics and Outcomes Research 2013, 5:471-479
Published Date: 23 September 2013